top of page
mAbs.png

NKA Bio is developing therapeutic antibodies 
to buy more time for life-saving care

About

About NKA Bio

Who:

NKA Bio is developing new medicines to improve critical care. Our lead product is NKA01, a temperature-stable antibody for trauma patients.

 

Problem:

When you are severely injured, it is a race against time to get to surgery. The average death occurs 8 minutes before lifesaving treatment can be delivered.

 

Solution:

But in the future, when minutes count, our antibody will buy hours. At NKA Bio, our treatment presses pause on death. With an injection of NKA01 by EMS, our drug could buy more time for medical teams to save your life.

2.png

The Problem

Problem
12.png

When you are severely injured, it is a race against time to get to surgery, because the average person dies 8 minutes before lifesaving treatment can be delivered.

In Addition to the 90,000 trauma patients who don't live long enough to get to a hospital... Every year:

Our Solution

Solution

Introducing NKA01

When minutes count, our antibody buys hours. NKA01 presses pause on death with a low-volume injection at the point of injury to buy more time for transport and lifesaving surgery.

Product:

Prefilled Syringe with our Anti-Shock Toxin Antibody for Injection by EMS during their standard treatment protocols to prepare the patient for transport.

Key Features:

Temperature stable and low volume for field use by EMS to immediately stabilize trauma patients and press pause on death to buy more time for transport to a trauma center for care.

Progress to Date:

Proof of Concept In Vivo with a Prototype. Lead Candidate Selected.

PreFilledSyring_Injection_edited.png
Pipeline

Pipeline

Pipeline_V2.png

World Health Organization

Team

Team
Gann Headshop Hopkins Surgery_edited.jpg

Shock Pioneer Behind Discovery 

(1932 - 2020)

Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.

48927.png

Donald S. Gann, MD

Susan Gann Hibbs

Chief Executive Officer

Corporate Vision

Investor Relations

Corporate Operations

  • LinkedIn
Lewis-Headshot.jpg

Lewis C. Hibbs III

Chief Technology Officer

R&D Lead

In Silico Platform Development

Research & Grant Writing

  • LinkedIn

Les E. Johnson

Regulatory Lead

CMC Expert

Quality & Risk Management

  • LinkedIn
74351762_2804088276281788_1017219491743924224_o_edited_edited.jpg

SUPPORT

Advisors

Trauma & Clinical Trials

MOORE_edited.png

Military Medicine

John-Ingari.png
image.png
LBH-BIOINCUBATOR.png

News & Updates

News & Media

Subscribe to Our Newsletter

Thanks for submitting!

bottom of page